Fundraising Fox

Xeltis

8 known investors

Xeltis develops implantable vascular devices that transform into living tissue using Restorex supramolecular polymer technology. The company targets patients requiring hemodialysis vascular access or cardiovascular replacements.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

ESEliane Schutte
Eliane SchutteinChief Executive Officer

Investors · 8

Kurma PartnersParis · $162K – $10.8M
VI PartnersAltendorf · $2.2M – $4.5M
Ysios CapitalBarcelona · $5.4M – $21.6M
EQT Life Sciencesreported · 2 sourcesLuxembourg · $11M – $66M
Invest-NLreported · 2 sourcesAmsterdam

Also in the syndicate · 3

DaVitaEuropean Innovation CouncilHorizon 3 Healthcarelead

In the news

Xeltis raises an additional €20.5m of funding to advance aXess toward FDA approval and US commercial launch - Med-Tech Insightsmed-techinsights.com · Aug 2026Xeltis raises $23.3M to bring vascular access device to USmassdevice.com · Jul 2026Xeltis Secures Additional Funding to Advance aXess Toward FDA Approval - TipRanks.comtipranks.com · Jul 2026Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue | EU-Startupseu-startups.com · Jul 2026Xeltis raises €20.5 million for medical implantsioplus.nl · Jul 2026Xeltis raises an additional €20.5m of funding to advanceglobenewswire.com · Jul 2026

Frequently asked questions

What does Xeltis do?
Xeltis develops implantable vascular devices that transform into living tissue using Restorex supramolecular polymer technology. The company targets patients requiring hemodialysis vascular access or cardiovascular replacements.
Who are Xeltis's investors?
Xeltis's investors include Kurma Partners, VI Partners, Ysios Capital, EQT Life Sciences, Invest-NL.